Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Comparative assessment of QM-based and MM-based models for prediction of protein-ligand binding affinity trends.
Journal: Physical chemistry chemical physics : PCCP
Published: June 06, 2022
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
Journal: Journal of medicinal chemistry
Published: June 03, 2021
Quantum Mechanical Investigation of Three-Dimensional Activity Cliffs Using the Molecules-in-Molecules Fragmentation-Based Method.
Journal: Journal of chemical information and modeling
Published: May 15, 2020
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
Journal: Bioorganic & medicinal chemistry
Published: August 06, 2019
Idea2Data: Toward a New Paradigm for Drug Discovery.
Journal: ACS medicinal chemistry letters
Published: October 18, 2018
Theoretical Study of Protein-Ligand Interactions Using the Molecules-in-Molecules Fragmentation-Based Method.
Journal: Journal of chemical theory and computation
Published: September 29, 2018
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Journal: The British journal of dermatology
Published: October 04, 2017
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
Journal: Journal of medicinal chemistry
Published: December 23, 2016
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 13, 2016
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 10, 2016
Fragment-based design of kinase inhibitors: a practical guide.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: February 25, 2015
Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.
Journal: Bioorganic & medicinal chemistry
Published: February 05, 2015
Last Updated: 09/26/2026